Temperature-stable formulations, and methods of development thereof

• US 20050153946A1
• Filed: 12/16/2004
• Published: 07/14/2005
• Est. Priority Date: 12/24/2003
• Status: Abandoned Application

• Current Assignee: Lupin Atlantis Holdings SA (Lupin Limited)
• Original Assignee: Collegium Pharmaceutical Incorporated
• Inventors: Tibbetts, Donald, Hirsh, Jane
• Application Number:
  US11/014,636
• Publication Number:
  US 20050153946A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

One embodiment of the present invention relates to a method of preparing a concentrated pharmaceutical formulation, comprising the steps of: combining in a container a therapeutic agent, a solvent and at least one pharmaceutically acceptable excipient to give a solution; adding to said solution a seed crystal of said compound to give a heterogeneous mixture; and observing the stability of said heterogeneous mixture.

Claims

1. An aqueous formulation, comprising:

water;

a therapeutic agent, selected from the group consisting of anti-inflammatory steroids and steroidal hormones, in an amount between about 0.001% and about 2.0% (w/v);

propylene glycol in an amount between about 13% and about 20% (w/v);

polyethylene glycol (PEG) in an amount between about 10% and about 50% (w/v);

a preservative;

a stabilizer; and

a pH buffering agent sufficient to maintain the pH of the aqueous formulation at between about 3.5 and about 8.0.

2. The aqueous formulation of claim 1, wherein the amount of propylene glycol is about 14% (w/v).

3. The aqueous formulation of claim 1, wherein the amount of preservative is between about 0.01% and about 0.08% (w/v).

4. The aqueous formulation of claim 1, wherein the amount of stabilizer is between about 0.005% and about 0.05% (w/v).

5. The aqueous formulation of claim 1, wherein the preservative is benzalkonium chloride.

6. The aqueous formulation of claim 1, wherein the stabilizer is disodium ethylenediaminetetraacetic acid (EDTA).

7. The aqueous formulation of claim 1, wherein the therapeutic agent is a steroidal hormone selected from the group consisting of benzestrol, broparoestriol, chlorotrianisene, clopormon, desogesterol, dienestriol, equilenin, equilin, estradiol, estriol, estrone, ethinyl estradiol, gestodene, hexestrol, lynestrenol, mestranol, methallenestril, methestrol, moxestriol, mytatrienediol, norethindrone, norethynodrel, norgestimate, quinestradiol, quinestrol, allylestrenol, altrenogest, anagestone, chlormadinone acetate, delmadinone acetate, demegestone, dimethisterone, drospirenone, dydrogesterone, ethisterone, ethynodiol, flurogestone acetate, gestonorone caproate, 17-hydroxy-16-methylene-X⁶-progesterone, 17α

-hydroxyprogesterone, medrogestone, medroxyprogesterone, megestrol acetate, melengestrol, norgesterone, norgestrel, norgestrienone, norvinisterone, pentagesterone, progesterone, promegestrone, trengestrone, boldenone, cloxotestosterone, fluoxymesterone, mesterolone, methandrostenolone, 17-methyltestosterone, 17α

-methyltestosterone-3-cylcopentyl enol ether, mibolerone, norethandrolone, normethandrone, oxandrolone, oxyrnesterone, oxymetholone, stanolone, stanozolol, testosterone, tismesterone, and mixtures of any of them.

8. The aqueous formulation of claim 1, wherein the therapeutic agent is an anti-inflammatory steroid selected from the group consisting of 21-acetoxypregnenolone, alclometasone, algestone, alisactide, amcinonide, aminoglutethimide, beclomethasone, beclomethasone dipropionate, betamethasone, betamethasone dipropionate, betamethasone adamantoate, budesonide, butixocort, chloropredinisone, ciclometasone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, deprodone, deprodone propionate, desonide, desoximetasone, dexamethasone, dexamethasonisonicotinate, diflorasone, diflucortolone, difluprednate, endrisone, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, flucortin, fluocortin butyl, flodexan fluclorolone acetonide, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formebolone, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate hydrocortamate, hydrocortisone, hydrocortisone aceponate, hydrocortisone butyrate, hydrocortisone-17-butyrate, icomethasone enbutyate, loteprednol etabonate, lotrisone, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, mometasone furoate monohydrate, mycophenolate mofetil, paramethasone, pranlukast, prednicarbate, prednisolone, prednisolone 25-diethylaminoacetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene promedrol, rimexolone, seratrodast, tipredane, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, triiostane, ulobetasol propionate, zileuton, and mixtures of any of them.

9. The aqueous formulation of claim 1, wherein the therapeutic agent is triamcinolone acetonide.

10. The aqueous formulation of claim 9, wherein the amount of propylene glycol is about 14% (w/v).

11. The aqueous formulation of claim 9, wherein the amount of preservative is between about 0.01% and about 0.08% (w/v).

12. The aqueous formulation of claim 9, wherein the amount of stabilizer is between about 0.005% and about 0.05% (w/v).

13. The aqueous formulation of claim 9, wherein the preservative is benzalkonium chloride.

14. The aqueous formulation of claim 9, wherein the stabilizer is disodium ethylenediaminetetraacetic acid (EDTA).

16. A kit, comprising a formulation of any one of claims 1-15.

17. The kit of claim 16, wherein said aqueous formulation further comprises an antihistamine, decongestant, ophthalmological, antibiotic, antifungal or irrigating solution.

18. The kit of claim 16, further comprising a solid or liquid dosage form of an antihistamine, decongestant, mucolytic agent, ophthalmological, or antibiotic.

19. The kit of claim 16, further comprising a separate irrigating solution.

20. A method of treating inflammation of a nasal mucosa or paranasal mucosa in a subject, comprising intranasally administering to a subject in need thereof a therapeutically effective amount of an aqueous formulation of any of claims 1-6 or 8-15.

15. An aqueous formulation, comprising:

water;

triamcinolone acetonide in an amount between about 0.01% and about 0.05% (w/v);

propylene glycol in an amount of about 14% (w/v);

PEG in an amount between about 35% and 45% (w/v);

benzalkonium chloride in an amount of about 0.05% (w/v);

disodium EDTA in an amount of about 0.05% (w/v);

citric acid in an amount of about 0.72% (w/v);

sodium citrate dihydrate in an amount of about 0.74% (w/v); and

an amount of a pH buffering agent sufficient to maintain the pH of the aqueous formulation between about 5 and 7.